# IBL Data Sheet

Code No. 10337

**Anti-Human**
**Tenascin-C (EGF Like Domain) (4F10TT) Mouse IgG MoAb**

Volume : 100 µg

**Introduction** : Tenascin-C (TN-C) is a component of the extracellular matrix (ECM) that has been shown to be involved in tissue interactions during fetal development and oncogenesis. It is glycoprotein consisting of six disulphide monomer isoforms being generated by alternative splicing. A high molecular weight variant that is generated by alternative splicing of RNAs of TN-C was found predominantly in breast, prostatic and colorectal cancers. The appearance of such a large TN-C isoform has been suggested to be of significance for tumour progression.

**Antigen** : Purified human glioma tenascin-C

**Source** : Mouse-Mouse hybridoma (Sp2/0×BALB/c mouse)

**Clone** : 4F10TT **Subclass** : IgG1

**Purification** : Purified with Protein A

**Form** : Lyophilized product from PBS containing 1 % BSA and 0.05 %$NaN_3$

**How to use** : 1.0 mL deionized water will be added to the product, then the concentration comes to 100 ug/mL

**Stability** : Lyophilized product, 5 years at 2 – 8 °C
: Solution, 2 years at –20 °C

**Application** : This antibody can be used in immunohistochemistry with formalin fixed paraffin embedded tissues after trypsin pretreatment by several techniques such as Avidin Biotin Complex (ABC) Method. The optimal dilution is about 5 µg/mL , however, the dilution rate should be optimized by each laboratories.
: This antibody can be used for western blotting in concentration of about 1 µg /mL.

**Specificity** : Specifically reacts with EGF like domain of all TN-C variants.
: Reacts with Mouse, Rat, Chicken and Rabbit.

**References** :


1. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn. 2000 Jun; 218(2):235-59.
2. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda M, Maki T, Nishikawa T, Sakakura T, Yoshida T. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol. 2002 Jul; 197(3):388-94.
3. Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, Yoshida K, Imanaka-Yoshida K, Yoshida T, Hiroe M, Tadokoro H, Irie T, Tanada S, Komuro I. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation. 2002 Sep 10;106(11):1397-402.
4. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest. 2001 Jul; 81(7):1015-24.
5. Yoshida T, Matsumoto E, Hanamura N, Kalembeyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol. 1997 Aug; 182 (4):421-8.
6. Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression.Am J Pathol. 2003 Jun;162 (6):1857-67.
7. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2006 Jun 6; 47 (11):2319-25.
8. Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, Watanabe S, Yoshida T, Adachi Y. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int. 2006 Apr; 26 (3):311-8.
9. Hasegawa M, Sudo A, Nagakura T, Hirata H, Kinoshita N, Yoshida T, Uchida A. Tenascin-C levels in pseudosynovial fluid of loose hip prostheses.Scand J Rheumatol. 2005 Nov-Dec; 34 (6):464-8.
10. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, Yoshida T, Hiroe M. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol. 2005 Mar; 205 (4):460-7.
11. Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, Yoshida T, Uchida A. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol. 2004 Oct; 31 (10):2021-6.
12. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol. 2004 Apr; 19 (2):517-25.
13. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer. 1997 Sep 26; 73(1):10-5.


*For research use only, not for use in diagnostic procedures.*


Distributed by:

Immuno-Biological Laboratories, Inc.
8201 Central Ave NE, Suite P
Minneapolis, MN 55432

Toll-Free: 888-523-1246
Email: info@IBL-America.com
Web: www.IBL-America.com

Immuno-Biological
Laboratories Co., Ltd.